Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Investing > India’s Serum Institute to invest $68 million in UK vaccine maker Oxford Biomedica
    Investing

    India’s Serum Institute to invest $68 million in UK vaccine maker Oxford Biomedica

    Published by maria gbaf

    Posted on September 23, 2021

    2 min read

    Last updated: February 2, 2026

    Image showcasing the Serum Institute of India, emphasizing its $68 million investment in Oxford Biomedica for COVID-19 vaccine production, highlighting the collaboration in vaccine development.
    Serum Institute of India to invest in Oxford Biomedica's vaccine development - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Quick Summary

    Serum Institute of India invests $68 million in Oxford Biomedica to expand COVID-19 vaccine production, acquiring a 3.9% stake.

    Serum Institute to Invest $68M in UK Vaccine Maker Oxford Biomedica

    (Reuters) -Vaccine maker Serum Institute of India (SII) will invest 50 million pounds ($68 million) in Oxford Biomedica to help fund the development of a plant that manufactures COVID-19 shots, the British company said on Wednesday.

    Serum – the world’s largest vaccine manufacturer by volume – and Oxford Biomedica both produce AstraZeneca’s COVID-19 vaccine.

    Serum Life Sciences Ltd, a unit of India-based SII, will pick up a 3.9% stake in Oxford Biomedica as part of the deal.

    Oxford Biomedica, spun off from Oxford University in 1995, said it would use the funds to develop the fallow area at its Oxbox plant into a manufacturing space expected to come online in mid-2023.

    The Oxbox plant currently makes COVID-19 shots, and the new space is expected to include a capacity to produce viral vector-based products including vaccines, Biomedica said.

    Shares of the British firm were up 5% on the London Stock Exchange, as of 0745 GMT.

    Serum’s investment comes four months after Oxford Biomedica doubled its sales estimates from the AstraZeneca shot to more than 100 million pounds by 2021-end.

    A representative for SII did not immediately respond to Reuters’ request for a comment.

    For Serum, the deal is the second in as many weeks, following its planned purchase of a 15% stake in Indian drugmaker Biocon’s biologics unit.

    The Oxford-based company said on Wednesday it swung to a profit after its half-yearly revenue more than doubled.

    ($1 = 0.7327 pounds)

    (Reporting by Aby Jose Koilparambil and Sachin Ravikumar in Bengaluru, Editing by Sherry Jacob-Phillips)

    Key Takeaways

    • •Serum Institute of India invests $68 million in Oxford Biomedica.
    • •Investment aims to expand COVID-19 vaccine production capacity.
    • •Serum will acquire a 3.9% stake in Oxford Biomedica.
    • •The Oxbox plant will develop new manufacturing space by mid-2023.
    • •Oxford Biomedica's shares rose 5% following the announcement.

    Frequently Asked Questions about India’s Serum Institute to invest $68 million in UK vaccine maker Oxford Biomedica

    1What is the main topic?

    The main topic is Serum Institute of India's investment in Oxford Biomedica to enhance COVID-19 vaccine production.

    2What is the investment amount?

    Serum Institute of India is investing $68 million in Oxford Biomedica.

    3What will the investment be used for?

    The investment will fund the development of a new manufacturing space at the Oxbox plant.

    More from Investing

    Explore more articles in the Investing category

    Image for Understanding the Factors Shaping Bitcoin’s Current Market Conditions
    Understanding the Factors Shaping Bitcoin’s Current Market Conditions
    Image for Understanding Investment Management Consulting Services in the U.S. Market
    Understanding Investment Management Consulting Services in the U.S. Market
    Image for The Role of DST Sponsors and Service Providers in Delaware Statutory Trusts
    The Role of DST Sponsors and Service Providers in Delaware Statutory Trusts
    Image for Understanding Self-Directed IRA Structures and Platform Models
    Understanding Self-Directed IRA Structures and Platform Models
    Image for 1031 Exchanges and Delaware Statutory Trusts: What Investors Need to Know
    1031 Exchanges and Delaware Statutory Trusts: What Investors Need to Know
    Image for Excellence in Innovation – Strategic Investment & Economic Transformation Egypt 2025
    Excellence in Innovation – Strategic Investment & Economic Transformation Egypt 2025
    Image for What Is the Average Pension Pot in the UK? (By Age)
    What Is the Average Pension Pot in the UK? (By Age)
    Image for From Money Printing to Market Surge: The Macro Forces Driving Crypto in 2026
    From Money Printing to Market Surge: The Macro Forces Driving Crypto in 2026
    Image for  Millennials Aren’t Ignoring Retirement. They’re Rebuilding It.
    Millennials Aren’t Ignoring Retirement. They’re Rebuilding It.
    Image for BridgeWise Launches FixedWise, the First AI Solution Bringing Granular Bond Intelligence to the European Market
    BridgeWise Launches FixedWise, the First AI Solution Bringing Granular Bond Intelligence to the European Market
    Image for Why Financial Advisors Are Rethinking Gold Allocations
    Why Financial Advisors Are Rethinking Gold Allocations
    Image for From Opaque to Investable: Yaniv Bertele's Blueprint for Transparent Alternatives
    From Opaque to Investable: Yaniv Bertele's Blueprint for Transparent Alternatives
    View All Investing Posts
    Previous Investing PostChina’s mom-and-pop investors, builders and homebuyers caught in Evergrande debt crisis
    Next Investing PostAsian shares gain but Evergrande jitters keep investors on edge